Associated Papers
Cis or trans: a puzzle of Parkin activation mechanism.
Sherawat M et al.
Essays in Biochemistry, 2026
Mitophagy in the pathogenesis and management of disease.
Wang Q et al.
Cell Research, 2026
Bridging pleiotropic mechanisms in leprosy type-1 reactions and neurodegenerative diseases.
Fava VM et al.
Scientific Reports, 2025
The genetic architecture of Parkinson's disease on the Island of Crete.
Boura I et al.
Npj Parkinson's Disease, 2025
The Global Landscape of Genetic Variation in Parkinson's disease: Multi-Ancestry Insights into Established Disease Genes and their Translational Relevance.
Lange LM et al.
Medrxiv : the Preprint Server for Health Sciences, 2025
Parkin mediates the mitochondrial dysfunction through mRpL18.
Ti X et al.
The Journal of Biological Chemistry, 2025
Population-Specific Differences in Pathogenic Variants of Genes Associated with Monogenic Parkinson's Disease.
Flores-Ocampo V et al.
Genes, 2025
Targeting mitophagy in neurodegenerative diseases.
Antico O et al.
Nature Reviews. Drug Discovery, 2025
SFXN2 contributes mitochondrial dysfunction-induced apoptosis as a substrate of Parkin.
Luo S et al.
Frontiers in Cellular Neuroscience, 2025
Parkinson's Disease Pathogenic Variants: Cross-Ancestry Analysis and Microarray Data Validation.
Hong S et al.
Medrxiv : the Preprint Server for Health Sciences, 2024
Therapeutic potential of Parkin and its regulation in Parkinson's disease.
Safreena N et al.
Biochemical Pharmacology, 2024
Activation of parkin by a molecular glue.
Sauvé V et al.
Nature Communications, 2024
Parkinson's disease variant detection and disclosure: PD GENEration, a North American study.
Cook L et al.
Brain : a Journal of Neurology, 2024
Relevance of genetic testing in the gene-targeted trial era: the Rostock Parkinson's disease study.
Westenberger A et al.
Brain : a Journal of Neurology, 2024
PRKN-linked familial Parkinson's disease: cellular and molecular mechanisms of disease-linked variants.
Clausen L et al.
Cellular and Molecular Life Sciences : Cmls, 2024
Interplay between α-synuclein and parkin genes: Insights of Parkinson's disease.
Sharma K et al.
Molecular Biology Reports, 2024
Genotype-phenotype correlation in PRKN-associated Parkinson's disease.
Menon PJ et al.
Npj Parkinson's Disease, 2024
A mutational atlas for Parkin proteostasis.
Clausen L et al.
Nature Communications, 2024
In search for mitochondrial biomarkers of Parkinson's disease: Findings in parkin-mutant human fibroblasts.
Kamienieva I et al.
Biochimica Et Biophysica Acta. Molecular Basis of Disease, 2023
Structure-based design and characterization of Parkin-activating mutations.
Stevens MU et al.
Life Science Alliance, 2023
High-content phenotypic screen to identify small molecule enhancers of Parkin-dependent ubiquitination and mitophagy.
Tufi R et al.
Slas Discovery : Advancing Life Sciences R & D, 2023
The Etiology of Parkinson's Disease: New Perspectives from Gene-Environment Interactions.
Bogers JS et al.
Journal of Parkinson's Disease, 2023
Post-translational modification and mitochondrial function in Parkinson's disease.
Luo S et al.
Frontiers in Molecular Neuroscience, 2023
Structure of the second phosphoubiquitin-binding site in parkin.
Fakih R et al.
The Journal of Biological Chemistry, 2022
The Role of NEDD4 E3 Ubiquitin-Protein Ligases in Parkinson's Disease.
Conway JA et al.
Genes, 2022
Benchmarking a highly selective USP30 inhibitor for enhancement of mitophagy and pexophagy.
Rusilowicz-Jones EV et al.
Life Science Alliance, 2022
Comparative analysis of web-based programs for single amino acid substitutions in proteins.
Choudhury A et al.
Plos One, 2022
Animal Models of Autosomal Recessive Parkinsonism.
Bastioli G et al.
Biomedicines, 2021
Assessing the relationship between monoallelic PRKN mutations and Parkinson's risk.
Lubbe SJ et al.
Human Molecular Genetics, 2021
Interaction between Parkin and α-Synuclein in PARK2-Mediated Parkinson's Disease.
Madsen DA et al.
Cells, 2021
Multitasking guardian of mitochondrial quality: Parkin function and Parkinson's disease.
Kamienieva I et al.
Translational Neurodegeneration, 2021
Analysis of Heterozygous PRKN Variants and Copy-Number Variations in Parkinson's Disease.
Yu E et al.
Movement Disorders : Official Journal of the Movement Disorder Society, 2021
Exome sequencing in BRCA1-2 candidate familias: the contribution of other cancer susceptibility genes
Doddato G et al.
Frontiers in Oncology, 2021
Characterization of Recessive Parkinson Disease in a Large Multicenter Study.
Lesage S et al.
Annals of Neurology, 2020
Oxidative switch drives mitophagy defects in dopaminergic parkin mutant patient neurons.
Schwartzentruber A et al.
Scientific Reports, 2020
Tollip coordinates Parkin-dependent trafficking of mitochondrial-derived vesicles.
Ryan TA et al.
The Embo Journal, 2020
Mitochondrial E3 Ubiquitin Ligase Parkin: Relationships with Other Causal Proteins in Familial Parkinson's Disease and Its Substrate-Involved Mouse Experimental Models.
Torii S et al.
International Journal of Molecular Sciences, 2020
Structural analysis of the effects of mutations in Ubl domain of Parkin leading to Parkinson's disease.
Biswas S et al.
Gene, 2020
Genetic predispositions of Parkinson's disease revealed in patient-derived brain cells.
Tran J et al.
Npj Parkinson's Disease, 2020
The PARK2 Mutation Associated with Parkinson's Disease Enhances the Vulnerability of Peripheral Blood Lymphocytes to Paraquat.
Ming F et al.
Biomed Research International, 2020
The landscape of Parkin variants reveals pathogenic mechanisms and therapeutic targets in Parkinson's disease.
Yi W et al.
Human Molecular Genetics, 2019
Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson's disease.
Fava VM et al.
Proceedings of the National Academy of Sciences of the United States of America, 2019